| Literature DB >> 24517240 |
Eva Klingberg, Mattias Lorentzon, Jan Göthlin, Dan Mellström, Mats Geijer, Claes Ohlsson, Elizabeth J Atkinson, Sundeep Khosla, Hans Carlsten, Helena Forsblad-d'Elia.
Abstract
INTRODUCTION: Osteoporosis of the axial skeleton is a known complication of ankylosing spondylitis (AS), but bone loss affecting the peripheral skeleton is less studied. This study on volumetric bone mineral density (vBMD) and bone microarchitecture in AS was conducted to compare peripheral vBMD in AS patients with that in healthy controls, to study vBMD in axial compared with peripheral bone, and to explore the relation between vertebral fractures, spinal osteoproliferation, and peripheral bone microarchitecture and density.Entities:
Mesh:
Year: 2013 PMID: 24517240 PMCID: PMC3978766 DOI: 10.1186/ar4368
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Characteristics of 69 male patients with ankylosing spondylitis in western Sweden
| Age, years | | 48 (17, 78) | 49 ± 15 |
| Years since symptom onset | | 20 (2, 55) | 23 ± 14 |
| Present or past iritis | 37 (54) | | |
| Present or past synovitis | 37 (54) | | |
| Patients with a vertebral fracture | 8 (12) | | |
| mSASSS | | 8 (0, 72) | 19 ± 21 |
| BASMI, score | | 3.0 (1.0, 7.2) | 3.2 ± 1.6 |
| BASDAI, score | | 2.7 (0.2, 7.9) | 3.1 ± 2.0 |
| ASDAS, score | | 2.1 (1.0, 4.4) | 2.3 ± 0.9 |
| BAS-G | | 2.2 (0, 9.8) | 3.0 ± 2.7 |
| BASFI, score | | 2.0 (0, 8.7) | 2.6 ± 2.2 |
| ESR, mm/h | | 10 (2, 73) | 14 ± 12 |
| CRP, mg/L | | 5 (3, 71) | 9 ± 12 |
| HLA-B27 positive | 65 (94) | | |
| Patients taking NSAID | 52 (75) | | |
| Patients taking glucocorticoid | 1 (1) | | |
| Patients taking DMARD | 21 (30) | | |
| Methotrexate | 13 (19) | | |
| Sulfasalazine | 5 (7) | | |
| TNF inhibitors | 15 (22) |
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, BAS Functional Index; BASG1, BAS Patient Global score; BASMI, BAS Metrology Index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NSAID, nonsteroidal antiinflammatory drug; DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score.
Comparison of the demographics and HRpQCT parameters in the AS patients and healthy age-matched controls
| | | |||
|---|---|---|---|---|
| Demographics | Male % | 100 | 100 | |
| | Age (years) | 49 ± 14 | 49 ± 14 | 0.993 |
| | BMI kg/m2 | 26.6 ± 4.4 | 27.8 ± 4.6 | 0.117 |
| | Height cm | 177 ± 7 | 179 ± 7 | 0.358 |
| | Weight kg | 84 ± 14 | 89 ± 16 | 0.052 |
| HRpQCT radius | DTrab mg/cm3 | 181 ± 39 | 187 ± 39 | 0.460 |
| | DCort mg/cm3 | 850 ± 55 | 874 ± 42 | 0.007 |
| HRpQCT tibia | DTrab mg/cm3 | 187 ± 35 | 201 ± 41 | 0.033 |
| DCort mg/cm3 | 844 ± 53 | 845 ± 44 | 0.944 |
The youngest AS patient was excluded from this analysis because of lack of a healthy control. Calculations on the tibia were made on 68 patients and controls and on radius of 61 patients and controls. The HRpQCT measurements of the radius from seven AS patients had to be excluded towing to motion artefacts. BMI, body mass index; DCort, vBMD of cortical peripheral bone; DTrab, vBMD of trabecular peripheral bone; HRpQCT, high-resolution peripheral quantitative computed tomography.
Figure 1The correlations between trabecular volumetric BMD in the lumbar spine, ultradistal radius, and tibia.
The correlation (Spearman rho) between the HRpQCT parameters, age, lumbar QCT, and mSASSS in the AS patients
| -0.471 | -0.473 | -0.507 | -0.040 | 0.166 | -0.337 | -0.228 | 0.540 | 0.055 | |
| 0.762 | 0.763 | 0.737 | 0.106 | -0.304 | 0.425 | 0.420 | -0.480 | - 0.136 | |
| 0.296 | 0.298 | 0.152 | 0.296 | - 0.341 | 0.123 | 0.152 | 0.032 | 0.006 | |
| - 0.400 | - 0.400 | - 0.528 | 0.077 | 0.039 | - 0.192 | - 0.196 | 0.352 | 0.022 | |
| (mg/cm3) | (%) | (μm) | (mm-1) | (μm) | (mg/cm3) | (μm) | (%) | (μm) | |
| - 0.470 | - 0.471 | - 0.479 | - 0.185 | 0.246 | - 0.436 | - 0.202 | 0.521 | 0.210 | |
| 0.084 | |||||||||
| 0.712 | 0.714 | 0.523 | 0.363 | - 0.443 | 0.454 | 0.403 | - 0.496 | - 0.437 | |
| 0.336 | 0.336 | 0.027 | 0.356 | - 0.367 | 0.135 | 0.151 | - 0.102 | - 0.162 | |
| - 0.475 | - 0.475 | - 0.488 | - 0.105 | 0.176 | - 0.315 | -0.161 | 0.363 | 0.169 | |
BV/TV, trabecular bone volume fraction; Cort, cortical; DCort, vBMD of cortical peripheral bone; DTrab, vBMD of trabecular peripheral bone; CortTh, cortical thickness peripheral bone; CtPo, cortical porosity; CtPoDiam, mean cortical pore diameter; HRpQCT, high-resolution peripheral quantitative computed tomography; Lumb, lumbar; TbN, trabecular number peripheral bone; TbSp, trabecular separation peripheral bone; Tbth,trabecular thickness peripheral bone; Trab, trabecular; vBMD, volumetric bone mineral density; QCT, quantitative computed tomography.
Figure 2HRpQCT images of ultradistal radius and tibia. (A) 3D representation of ultradistal tibia. AS patient with normal BMD. (B) 3D representation of ultradistal radius. AS patient with osteoporosis. (C) 2D representation of ultradistal tibia. AS patient with normal BMD. (D) 2D representation of ultradistal tibia. AS patients with lumbar osteoporosis. Note the low trabecular number and thickness, high trabecular separation, and low cortical thickness.
BMD and microarchitectural parameters in AS patients with a vertebral fracture compared with age-matched AS patients without a vertebral fracture
| | | ||||
|---|---|---|---|---|---|
| | Age (years) | 55.9 ± 12.4 | 55.6 ± 12.8 | -0.01 | 0.955 |
| QCT lumbar spine | Trab vBMD (mg/cm3) | 117.17 ± 34.35 | 92.09 ± 40.94 | -21.4 | 0.128 |
| | Cort vBMD (mg/cm3) | 366.11 ± 81.62 | 285.45 ± 52.77 | -22.0 | 0.019 |
| DXA BMD | AP lumbar (g/cm2) | 1.10 ± 0.11 | 0.98 ± 0.13 | -10.9 | 0.018 |
| | Lat lumbar (g/cm2) | 0.80 ± 0.11 | 0.68 ± 0.10 | -15.0 | 0.021 |
| | Lumb vBMD (g/cm3) | 0.20 ± 0.03 | 0.17 ± 0.03 | -15.0 | 0.048 |
| | Femoral neck (g/cm2) | 0.80 ± 0.11 | 0.66 ± 0.12 | -17.5 | 0.009 |
| | Total hip (g/cm2) | 1.00 ± 0.10 | 0.83 ± 0.13 | -17.0 | 0.002 |
| | Radius 1/3 (g/cm2) | 0.79 ± 0.05 | 0.78 ± 0.08 | -1.3 | 0.672 |
| | Total radius (g/cm2) | 0.66 ± 0.05 | 0.62 ± 0.07 | -6.1 | 0.188 |
| HRpQCT | DTrab (mg/cm3) | 195.42 ± 40.31 | 147.20 ± 27.10 | -24.7 | 0.010 |
| Radius | |||||
| | BV/TV (%) | 16.3 ± 3.4 | 12.3 ± 2.3 | -25.0 | 0.010 |
| | Tbth (μm) | 83.1 ± 19.9 | 65.1 ± 7.9 | -12.5 | 0.034 |
| | TbN (per mm) | 1.98 ± 0.26 | 1.88 ± 0.23 | -5.1 | 0.388 |
| | TbSp (μm) | 430.0 ± 66.1 | 473.1 ± 64.7 | +9.3 | 0.169 |
| | DCort (mg/cm3) | 862.81 ± 38.45 | 810.70 ± 68.01 | -6.0 | 0.032 |
| | CortTh (μm) | 901 ± 163 | 637 ± 181 | -28.9 | 0.003 |
| | CortCSA (mm2) | 76.81 ± 11.63 | 55.11 ± 14.17 | -28.3 | 0.001 |
| | CtPo (%) | 2.65 ± 0.97 | 2.39 ± 1.07 | -9.8 | 0.548 |
| | CtPoDiam (μm) | 172 ± 18 | 165 ± 15 | -4.1 | 0.548 |
| HRpQCT | DTrab (mg/cm3) | 189.52 ± 25.76 | 155.59 ± 39.46 | -17.9 | 0.052 |
| Tibia | |||||
| | BV/TV (%) | 15.8 ± 2.1 | 13.0 ± 3.3 | -18.8 | 0.050 |
| | Tbth (μm) | 78.6 ± 9.4 | 68.4 ± 9.4 | -12.5 | 0.020 |
| | TbN (per mm) | 2.01 ± 0.18 | 1.88 ± 0.26 | -6.4 | 0.149 |
| | TbSp (μm) | 421.9 ± 44.8 | 474.6 ± 89.1 | +14.3 | 0.150 |
| | DCort (mg/cm3) | 848.24 ± 51.18 | 810.19 ± 83.08 | -4.5 | 0.263 |
| | CortTh (μm) | 1,303 ± 297 | 946 ± 352 | -26.9 | 0.016 |
| | CortCSA (mm2) | 151.94 ± 26.71 | 115.50 ± 38.91 | -24.0 | 0.013 |
| | Ct Po (%) | 7.27 ± 2.94 | 7.54 ± 3.27 | +3.7 | 0.881 |
| CtPoDiam (μm) | 189 ± 16 | 194 ± 17 | +2.6 | 0.417 |
Difference (%), mean of fractured – mean of nonfractured/mean of nonfractured; BMD, bone mineral density; BV/TV, trabecular bone volume fraction; Cort, cortical; DCort, vBMD of cortical peripheral bone; DTrab, vBMD of trabecular peripheral bone; DXA, dual-energy x-ray absorptiometry; CortCSA, cortical cross-sectional area peripheral bone; CortTh,cortical thickness peripheral bone, CtPo = cortical porosity; CtPoDiam, mean cortical pore diameter; HRpQCT, high-resolution peripheral quantitative computed tomography; TbN, trabecular number peripheral bone; TbSp, trabecular separation peripheral bone; Tbth, trabecular thickness peripheral bone; Trab, trabecular; vBMD, volumetric BMD; QCT, quantitative computed tomography.